The billionaire’s low-cost pharmaceutical company began offering brand name drugs in early March and has added several since.
The addition of Yusimry, manufactured by Coherus BioSciences, to Cost Plus Drugs offerings marks a move by the company to begin “to make biologics accessible to all,” the company said in a tweet.
“We are excited to disrupt the high-cost biologic space by offering Yusimry, a biosimilar of Humira, one of the highest cost drugs in America,” Alex Oshmyansky, co-founder and CEO of Mark Cuban Cost Plus Drug Company said in a statement.
Without insurance, purchasing the drug from Mark Cuban’s pharmacy will cost around $570.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
